Aspirin resistance in young men with Type 2 diabetes

Subhashini Yaturu, Emmy Dier, Huadong Cui, Shaker Mousa

Endocrinology and Metabolism, Stratton VA Medical Center, Albany, USA.
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.

DOI: 10.4236/jdm.2014.41013                

Abstract

Objective: Aspirin resistance (AR) or poor response to aspirin is said to be high among subjects with diabetes and more so in patients with poor glycemic control. The aim of our study was to evaluate the prevalence of AR among subjects with diabetes with moderate glycemic control and its association with inflammatory markers and cytokines. Design: This is a single-center open-label prospective clinical study. Methods: The study included 142 young male veterans (mean age of 49years) with Type 2 diabetes, with HbA1C of 7.7 ± 1.1. Urinary 11-dehydro-thromboxane beta-2 (11DhTx2) concentrations measured by immunoassay are the primary outcome measures. Results: Urinary 11DhTxB₂ levels ≥ 1500 pg/mg of creatinine is considered as AR. Approximately 53% of subjects had AR. There are no significant differences in the clinical parameters, such as age, history of hypertension or BMI, waist to hip ratio; as well as biochemical parameters, such as HbA1C, lipid parameters or serum creatinine, between subjects with or without AR. Levels of 11DhTxB₂ /cre correlated with history of CAD, abdominal fat content and IL-6 levels (p < 0.01) as well as abdominal fat content and IL-6 levels; duration of diabetes and history of CAD. Conclusions: Aspirin resistance is common in subjects with diabetes even with moderate control. Additional measures to improve aspirin response should be considered. Further studies with larger groups are needed to clarify the AR with various associated risk factors.

Keywords

Aspirin; Aspirin Resistance; Type 2 Diabetes; Men; CRP; IL-6; Adiponectin; Body Composition; Abdominal Fat

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	(2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 71-86. http://dx.doi.org/10.1136/bmj.324.7329.71
[2]	Pignone, M., et al. (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care, 33, 1395-1402. http://dx.doi.org/10.2337/dc10-0555
[3]	Rao, G.H. (1987) Influence of anti-platelet drugs on platelet-vessel wall interactions. Prostaglandins, Leukotrienes and Medicine, 30, 133-145. http://dx.doi.org/10.1016/0262-1746(87)90143-0
[4]	Eikelboom, J.W., et al., (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 105, 1650-1655. http://dx.doi.org/10.1161/01.CIR.0000013777.21160.07
[5]	Catella-Lawson, F., et al., (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. The New England Journal of Medicine, 345, 1809-1817. http://dx.doi.org/10.1056/NEJMoa003199
[6]	Halushka, M.K. and Halushka, P.V. (2002) Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation, 105, 1620-1622. http://dx.doi.org/10.1161/01.CIR.0000015422.86569.52
[7]	Modica, A., Karlsson, F. and Mooe, T. (2007) Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. Journal of Thrombosis and Haemostasis, 5, 507-511. http://dx.doi.org/10.1111/j.1538-7836.2007.02378.x
[8]	Guthikonda, S., et al. (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. Journal of Thrombosis and Haemostasis, 5, 490-496. http://dx.doi.org/10.1111/j.1538-7836.2007.02387.x
[9]	Zimmermann, N., et al. (2005) Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? European Journal Cardio-Thoracic Surgery, 27, 606-610. http://dx.doi.org/10.1016/j.ejcts.2004.12.010
[10]	Zimmermann, N., et al. (2003) Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation, 108, 542-547. http://dx.doi.org/10.1161/01.CIR. 0000081770.51929.5A
[11]	Okada, S., et al. (2011) Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: A subanalysis of the JPAD trial. Diabetes Care, 34, 1277-1283. http://dx.doi.org/10.2337/dc10-2451
[12]	DiChiara, J., et al. (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 56, 3014-3019. http://dx.doi.org/10.2337/db07-0707
[13]	De Berardis, G., et al. (2007) Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials, 8, 21. http://dx.doi.org/10.1186/1745-6215-8-21
[14]	Tirnaksiz, E., et al. (2009) Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. Journal of Thrombosis and Haemostasis, 27, 24-28. http://dx.doi.org/10.1007/s11239-007-0154-1
[15]	Tekten, T., et al. (2004) The effect of atorvastatin on platelet function in patients with coronary artery disease. Acta Cardiologica, 59, 311-315. http://dx.doi.org/10.2143/AC.59.3.2005187
[16]	Yassine, H.N., et al. (2010) Effect of glucose or fat challenge on aspirin resistance in diabetes. International Journal of Endocrinology, 2010, Article ID: 820876.